US · SNTI
Senti Biosciences, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- South San Francisco, CA 94080
- Website
- sentibio.com
Price · as of 2024-12-31
$1.02
Market cap 24.82M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $25.28 | +2,378.43% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $98.80 | $68.88 | $0.00 | $0.00 | $0.00 |
| 2022 | $13.55 | $12.65 | $0.00 | $0.00 | $0.00 |
| 2023 | $4.28 | $2.57 | $0.00 | $0.00 | $479.45 |
| 2024 | $3.52 | $25.28 |
AI valuation
Our deep-learning model estimates Senti Biosciences, Inc.'s (SNTI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $25.28
- Current price
- $1.02
- AI upside
- +2,378.43%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SNTI | Senti Biosciences, Inc. | $1.02 | 24.82M | +2,378% | — | — | — | -0.31 | 0.63 | — | -0.03 | — | 0.63 | 0.00% | — | — | -114.06% | -153.24% | -48.58% | 1.31 | — | 4.49 | 3.81 | 0.27 | -4513.00% | -10000.00% | -3571.00% | -256.05% | -3.15 | -103.99% | 0.00% | 0.00% | 101.22% | -0.03 | -0.04 | — | -5.61 |
| ALGS | Aligos Therapeutics, Inc. | $7.03 | 43.26M | -26% | -26% | — | +18,737% | -0.62 | -2.80 | 20.55 | -0.38 | -0.12 | -2.80 | 100.00% | -2259.92% | -3326.01% | -415.84% | 162.06% | -118.41% | -0.29 | — | 2.86 | 2.62 | 0.33 | 49489.00% | -7460.00% | 235.00% | -99.76% | -3.71 | 147.01% | 0.00% | 0.00% | 0.00% | -0.36 | -0.40 | 8.24 | -15.30 |
| BRNS | Barinthus Biotherapeutics… | $0.58 | 23.85M | +43,665% | +73% | — | — | -0.63 | 0.30 | 2.59 | 1.08 | — | 0.36 | 100.00% | -454.07% | -408.00% | -38.62% | -152.56% | -32.65% | 0.09 | -1282.45 | 8.03 | 7.90 | 1.78 | -1885.00% | 176646.00% | -4705.00% | -76.97% | -1.85 | -67.01% | 0.00% | 0.00% | 0.00% | 0.88 | 2.01 | -4.00 | -1.79 |
| COEP | Coeptis Therapeutics, Inc… | $12.04 | 42.29M | — | — | — | — | -1.87 | 6.40 | — | -2.25 | -0.32 | 7.72 | 0.00% | — | — | -290.10% | -247.64% | -128.12% | 0.44 | -25.38 | 0.23 | 0.12 | -0.09 | 58072.00% | — | -815.00% | -32.60% | -1.47 | -163.77% | 0.00% | 0.00% | 0.00% | -2.11 | -3.20 | — | -17.20 |
| CUE | Cue Biopharma, Inc. | $0.28 | 22.08M | +11,310% | +57% | — | — | -1.52 | 3.54 | 6.67 | -1.26 | — | 3.54 | 100.00% | -446.86% | -437.97% | -149.03% | -1327.36% | -86.80% | 0.51 | -52.14 | 1.84 | 1.78 | 0.36 | -3514.00% | 6916.00% | -892.00% | -58.74% | -2.65 | -1164.08% | 0.00% | 0.00% | 0.00% | -1.14 | -1.30 | 5.11 | -15.88 |
| GNTA | Genenta Science S.p.A. | $0.99 | 18.96M | — | — | — | — | -6.66 | 4.75 | — | -4.80 | — | 4.78 | 0.00% | — | — | -54.13% | -1295.77% | -47.95% | 0.00 | — | 6.89 | 6.72 | 0.47 | -2344.00% | — | -4434.00% | -10.53% | -2.97 | -828.69% | 0.00% | 0.00% | 1.48% | -4.78 | -7.48 | — | 8.82 |
| IPSC | Century Therapeutics, Inc… | $2.32 | 202.78M | +1,581% | -88% | — | — | -0.41 | 0.32 | 7.82 | 0.75 | — | 0.41 | 100.00% | -2096.48% | -1920.87% | -73.14% | -320.94% | -35.46% | 0.33 | — | 1.50 | 1.47 | 0.04 | -3000.00% | 19481.00% | 804.00% | -214.09% | -0.85 | -256.24% | 0.00% | 0.00% | 10.59% | 0.61 | 0.76 | -12.74 | -3.99 |
| KPTI | Karyopharm Therapeutics I… | $9.41 | 80.34M | +75% | -59% | — | — | -0.53 | -0.36 | 0.72 | -3.04 | -0.59 | -0.36 | 95.93% | -62.10% | -134.21% | 81.86% | 81.25% | -143.71% | -0.80 | -1.98 | 1.12 | 0.98 | -1.91 | 9054.00% | 57.00% | -4095.00% | -71.87% | -0.82 | 67.51% | 0.00% | 0.00% | 0.00% | -3.03 | -3.65 | 1.88 | -23.86 |
| MDCX | Medicus Pharma Ltd. Commo… | $1.53 | 37.8M | — | — | — | — | -2.63 | 9.36 | — | -2.29 | — | 9.36 | 0.00% | — | — | -525.44% | 1700.21% | -295.90% | 0.10 | -35.21 | 2.33 | 1.81 | 0.34 | -2810.00% | — | 14643.00% | -34.93% | -4.44 | 1558.23% | 0.00% | 0.00% | 7.24% | -2.28 | -2.49 | — | -6.04 |
| XFOR | X4 Pharmaceuticals, Inc. | $3.44 | 39.24M | — | +23% | — | — | -1.89 | 3.20 | 27.68 | -1.70 | — | -13.60 | 68.83% | -1423.58% | -1464.61% | -102.26% | 1092.96% | -25.50% | 3.53 | -4.15 | 3.41 | 3.16 | -0.81 | -6731.00% | — | 3589.00% | -185.42% | -3.98 | 3940.16% | 0.00% | 0.00% | 0.00% | -1.29 | -0.36 | 18.30 | -4.74 |
About Senti Biosciences, Inc.
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
- CEO
- Timothy K. Lu
- Employees
- 34
- Beta
- 2.14
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.02) − 1 = — (DCF, example).